Market Research

Lung Cancer Diagnostics Market [Diagnostic Test Type: [Biopsy, Imaging Tests, Molecular Testing, and Others; Product Type: Consumables and Instruments; Cancer Type: Non-small cell lung cancer and Small Cell Lung Cancer; End-user: Hospitals, Clinics, Diagn

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 228 Pages Transparency Market Research Pvt. Ltd. October, 2024 TNPR19402233
Best Price Guarantee
Price from $5,795
Length 228 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date October, 2024
SKU TNPR19402233

Lung Cancer Diagnostics Market [Diagnostic Test Type: [Biopsy, Imaging Tests, Molecular Testing, and Others; Product Type: Consumables and Instruments; Cancer Type: Non-small cell lung cancer and Small Cell Lung Cancer; End-user: Hospitals, Clinics, Diagnostics & Imaging Centers, and Cancer Research Institutes] - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034


Lung Cancer Diagnostics Market – Scope of Report

TMR's report on the global lung cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global lung cancer diagnostics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lung cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the lung cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lung cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lung cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lung cancer diagnostics market.

The report delves into the competitive landscape of the global lung cancer diagnostics market. Key players operating in the global lung cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lung cancer diagnostics market profiled in this report.

Key Questions Answered in Global lung cancer diagnostics Market Report
  • What is the sales/revenue generated by lung cancer diagnostics across all regions during the forecast period?
  • What are the opportunities in the global lung cancer diagnostics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Lung Cancer Diagnostics Market – Research Objectives and Research Approach

The comprehensive report on the global lung cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lung cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lung cancer diagnostics market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Lung Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Cancer Diagnostics Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Recent Technological Advancements in Lung Cancer Diagnostics Industry
5.2. Insights on Emergence of Liquid Biopsy as a Lung Cancer Diagnostic Tool
5.3. Lung Cancer Diagnostics Pricing Trends
5.4. Regulatory Landscape across Key Regions / Countries
5.5. PORTER’s Five Forces Analysis
5.6. PESTEL Analysis
5.7. Value Chain Analysis
5.8. Go-To Market Strategy for New Entrants
5.9. Key Purchase Metrics for End-users
5.10. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions, funding and investments)
5.11. Benchmarking of the Products Offered by the Competitors
6. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Diagnostic Test Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Diagnostic Test Type, 2020-2034
6.3.1. Biopsy
6.3.1.1. Needle biopsy
6.3.1.2. Transbronchial biopsy
6.3.1.3. Thoracoscopic biopsy
6.3.1.4. Liquid Biopsy
6.3.1.4.1. Circulating Tumor Cells (CTCs)
6.3.1.4.2. Circulating Tumor DNA
6.3.1.4.3. Cell-Free RNA (cfRNA)
6.3.1.4.4. Exosomes
6.3.1.4.5. Proteomic Analysis
6.3.1.5. Others
6.3.2. Imaging Tests
6.3.2.1. Magnetic Resonance Imaging (MRI)
6.3.2.2. Computed Tomography (CT) Scan
6.3.2.3. Chest Ultrasound
6.3.2.4. Positron Emission Tomography (PET)
6.3.2.5. Other Imaging Tests
6.3.3. Molecular Testing
6.3.4. Others
6.4. Market Attractiveness By Diagnostic Test Type
7. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Product Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product Type, 2020-2034
7.3.1. Instruments
7.3.2. Consumables
7.4. Market Attractiveness By Product Type
8. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Cancer Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Cancer Type, 2020-2034
8.3.1. Non-small cell lung cancer (NSCLC)
8.3.2. Small cell lung cancer (SCLC)
8.4. Market Attractiveness By Cancer Type
9. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By End-user, 2020-2034
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Diagnostic & Imaging Centers
9.3.4. Cancer Research Institutes
9.4. Market Attractiveness By End-user
10. Global Lung Cancer Diagnostics Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Lung Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
11.2.1. Biopsy
11.2.1.1. Needle biopsy
11.2.1.2. Transbronchial biopsy
11.2.1.3. Thoracoscopic biopsy
11.2.1.4. Liquid Biopsy
11.2.1.4.1. Circulating Tumor Cells (CTCs)
11.2.1.4.2. Circulating Tumor DNA
11.2.1.4.3. Cell-Free RNA (cfRNA)
11.2.1.4.4. Exosomes
11.2.1.4.5. Proteomic Analysis
11.2.1.5. Others
11.2.2. Imaging Tests
11.2.2.1. Magnetic Resonance Imaging (MRI)
11.2.2.2. Computed Tomography (CT) Scan
11.2.2.3. Chest Ultrasound
11.2.2.4. Positron Emission Tomography (PET)
11.2.2.5. Other Imaging Tests
11.2.3. Molecular Testing
11.2.4. Others
11.3. Market Value Forecast By Product Type, 2020-2034
11.3.1. Instruments
11.3.2. Consumables
11.4. Market Value Forecast By Cancer Type, 2020-2034
11.4.1. Non-small cell lung cancer (NSCLC)
11.4.2. Small cell lung cancer (SCLC)
11.5. Market Value Forecast By End-user, 2020-2034
11.5.1. Hospitals
11.5.2. Clinics
11.5.3. Diagnostic & Imaging Centers
11.5.4. Cancer Research Institutes
11.6. Market Value Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Diagnostic Test Type
11.7.2. By Product Type
11.7.3. By Cancer Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Lung Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
12.2.1. Biopsy
12.2.1.1. Needle biopsy
12.2.1.2. Transbronchial biopsy
12.2.1.3. Thoracoscopic biopsy
12.2.1.4. Liquid Biopsy
12.2.1.4.1. Circulating Tumor Cells (CTCs)
12.2.1.4.2. Circulating Tumor DNA
12.2.1.4.3. Cell-Free RNA (cfRNA)
12.2.1.4.4. Exosomes
12.2.1.4.5. Proteomic Analysis
12.2.1.5. Others
12.2.2. Imaging Tests
12.2.2.1. Magnetic Resonance Imaging (MRI)
12.2.2.2. Computed Tomography (CT) Scan
12.2.2.3. Chest Ultrasound
12.2.2.4. Positron Emission Tomography (PET)
12.2.2.5. Other Imaging Tests
12.2.3. Molecular Testing
12.2.4. Others
12.3. Market Value Forecast By Product Type, 2020-2034
12.3.1. Instruments
12.3.2. Consumables
12.4. Market Value Forecast By Cancer Type, 2020-2034
12.4.1. Non-small cell lung cancer (NSCLC)
12.4.2. Small cell lung cancer (SCLC)
12.5. Market Value Forecast By End-user, 2020-2034
12.5.1. Hospitals
12.5.2. Clinics
12.5.3. Diagnostic & Imaging Centers
12.5.4. Cancer Research Institutes
12.6. Market Value Forecast By Country / Sub-region, 2020-2034
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Diagnostic Test Type
12.7.2. By Product Type
12.7.3. By Cancer Type
12.7.4. By End-user
12.7.5. By Country / Sub-region
13. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
13.2.1. Biopsy
13.2.1.1. Needle biopsy
13.2.1.2. Transbronchial biopsy
13.2.1.3. Thoracoscopic biopsy
13.2.1.4. Liquid Biopsy
13.2.1.4.1. Circulating Tumor Cells (CTCs)
13.2.1.4.2. Circulating Tumor DNA
13.2.1.4.3. Cell-Free RNA (cfRNA)
13.2.1.4.4. Exosomes
13.2.1.4.5. Proteomic Analysis
13.2.1.5. Others
13.2.2. Imaging Tests
13.2.2.1. Magnetic Resonance Imaging (MRI)
13.2.2.2. Computed Tomography (CT) Scan
13.2.2.3. Chest Ultrasound
13.2.2.4. Positron Emission Tomography (PET)
13.2.2.5. Other Imaging Tests
13.2.3. Molecular Testing
13.2.4. Others
13.3. Market Value Forecast By Product Type, 2020-2034
13.3.1. Instruments
13.3.2. Consumables
13.4. Market Value Forecast By Cancer Type, 2020-2034
13.4.1. Non-small cell lung cancer (NSCLC)
13.4.2. Small cell lung cancer (SCLC)
13.5. Market Value Forecast By End-user, 2020-2034
13.5.1. Hospitals
13.5.2. Clinics
13.5.3. Diagnostic & Imaging Centers
13.5.4. Cancer Research Institutes
13.6. Market Value Forecast By Country / Sub-region, 2020-2034
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Diagnostic Test Type
13.7.2. By Product Type
13.7.3. By Cancer Type
13.7.4. By End-user
13.7.5. By Country / Sub-region
14. Latin America Lung Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
14.2.1. Biopsy
14.2.1.1. Needle biopsy
14.2.1.2. Transbronchial biopsy
14.2.1.3. Thoracoscopic biopsy
14.2.1.4. Liquid Biopsy
14.2.1.4.1. Circulating Tumor Cells (CTCs)
14.2.1.4.2. Circulating Tumor DNA
14.2.1.4.3. Cell-Free RNA (cfRNA)
14.2.1.4.4. Exosomes
14.2.1.4.5. Proteomic Analysis
14.2.1.5. Others
14.2.2. Imaging Tests
14.2.2.1. Magnetic Resonance Imaging (MRI)
14.2.2.2. Computed Tomography (CT) Scan
14.2.2.3. Chest Ultrasound
14.2.2.4. Positron Emission Tomography (PET)
14.2.2.5. Other Imaging Tests
14.2.3. Molecular Testing
14.2.4. Others
14.3. Market Value Forecast By Product Type, 2020-2034
14.3.1. Instruments
14.3.2. Consumables
14.4. Market Value Forecast By Cancer Type, 2020-2034
14.4.1. Non-small cell lung cancer (NSCLC)
14.4.2. Small cell lung cancer (SCLC)
14.5. Market Value Forecast By End-user, 2020-2034
14.5.1. Hospitals
14.5.2. Clinics
14.5.3. Diagnostic & Imaging Centers
14.5.4. Cancer Research Institutes
14.6. Market Value Forecast By Country / Sub-region, 2020-2034
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Diagnostic Test Type
14.7.2. By Product Type
14.7.3. By Cancer Type
14.7.4. By End-user
14.7.5. By Country / Sub-region
15. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Diagnostic Test Type, 2020-2034
15.2.1. Biopsy
15.2.1.1. Needle biopsy
15.2.1.2. Transbronchial biopsy
15.2.1.3. Thoracoscopic biopsy
15.2.1.4. Liquid Biopsy
15.2.1.4.1. Circulating Tumor Cells (CTCs)
15.2.1.4.2. Circulating Tumor DNA
15.2.1.4.3. Cell-Free RNA (cfRNA)
15.2.1.4.4. Exosomes
15.2.1.4.5. Proteomic Analysis
15.2.1.5. Others
15.2.2. Imaging Tests
15.2.2.1. Magnetic Resonance Imaging (MRI)
15.2.2.2. Computed Tomography (CT) Scan
15.2.2.3. Chest Ultrasound
15.2.2.4. Positron Emission Tomography (PET)
15.2.2.5. Other Imaging Tests
15.2.3. Molecular Testing
15.2.4. Others
15.3. Market Value Forecast By Product Type, 2020-2034
15.3.1. Instruments
15.3.2. Consumables
15.4. Market Value Forecast By Cancer Type, 2020-2034
15.4.1. Non-small cell lung cancer (NSCLC)
15.4.2. Small cell lung cancer (SCLC)
15.5. Market Value Forecast By End-user, 2020-2034
15.5.1. Hospitals
15.5.2. Clinics
15.5.3. Diagnostic & Imaging Centers
15.5.4. Cancer Research Institutes
15.6. Market Value Forecast By Country / Sub-region, 2020-2034
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Diagnostic Test Type
15.7.2. By Product Type
15.7.3. By Cancer Type
15.7.4. By End-user
15.7.5. By Country / Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2023)
16.3. Company Profiles
16.3.1. Abbott
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategies
16.3.1.5. Recent Developments
16.3.2. Siemens Healthcare
16.3.2.1. Company Overview
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. Business Strategies
16.3.2.5. Recent Developments
16.3.3. GE Healthcare
16.3.3.1. Company Overview
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. Business Strategies
16.3.3.5. Recent Developments
16.3.4. Amoy Diagnostics Co.
16.3.4.1. Company Overview
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. Business Strategies
16.3.4.5. Recent Developments
16.3.5. Boditech Med, Inc.
16.3.5.1. Company Overview
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. Business Strategies
16.3.5.5. Recent Developments
16.3.6. Danaher
16.3.6.1. Company Overview
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. Business Strategies
16.3.6.5. Recent Developments
16.3.7. F. Hoffmann-La Roche
16.3.7.1. Company Overview
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. Business Strategies
16.3.7.5. Recent Developments
16.3.8. INOVIQ
16.3.8.1. Company Overview
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. Business Strategies
16.3.8.5. Recent Developments
16.3.9. MedGenome
16.3.9.1. Company Overview
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. Business Strategies
16.3.9.5. Recent Developments
16.3.10. Quest Diagnostics Incorporated
16.3.10.1. Company Overview
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. Business Strategies
16.3.10.5. Recent Developments
16.3.11. DiaSorin S.p.A.
16.3.11.1. Company Overview
16.3.11.2. Financial Overview
16.3.11.3. Product Portfolio
16.3.11.4. Business Strategies
16.3.11.5. Recent Developments
16.3.12. Oncocyte Corporation
16.3.12.1. Company Overview
16.3.12.2. Financial Overview
16.3.12.3. Product Portfolio
16.3.12.4. Business Strategies
16.3.12.5. Recent Developments
16.3.13. QIAGEN
16.3.13.1. Company Overview
16.3.13.2. Financial Overview
16.3.13.3. Product Portfolio
16.3.13.4. Business Strategies
16.3.13.5. Recent Developments
16.3.14. Thermo Fisher Scientific, Inc.
16.3.14.1. Company Overview
16.3.14.2. Financial Overview
16.3.14.3. Product Portfolio
16.3.14.4. Business Strategies
16.3.14.5. Recent Developments
16.3.15. NanoString Technologies
16.3.15.1. Company Overview
16.3.15.2. Financial Overview
16.3.15.3. Product Portfolio
16.3.15.4. Business Strategies
16.3.15.5. Recent Developments
16.3.16. Biodesix
16.3.16.1. Company Overview
16.3.16.2. Financial Overview
16.3.16.3. Product Portfolio
16.3.16.4. Business Strategies
16.3.16.5. Recent Developments
16.3.17. Other Prominent Players
16.3.17.1. Company Overview
16.3.17.2. Financial Overview
16.3.17.3. Product Portfolio
16.3.17.4. Business Strategies
16.3.17.5. Recent Developments

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings